Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jochen Schneider

Showing results (81-90 of 107) with videos related to

Pageof 11
Sort By:
Cancer Research|December 22, 2011
Hedgehog signaling inhibition blocks growth of resistant tumors through effects on tumor microenvironmentEmanuela Heller, Michelle A Hurchla, Jingyu Xiang, et al.
HIV Research & Clinical Practice|March 2, 2022
Switching to a NRTI-free 2 drug regimen (2DR) -a sub-analysis of the 48 weeks DUALIS study on metabolic and renal changesMalte Monin, Tim Kümmerle, Jochen Schneider, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|September 21, 2021
Pre-medication with oral anticoagulants is associated with better outcomes in a large multinational COVID-19 cohort with cardiovascular comorbiditiesMarina Rieder, Nadine Gauchel, Klaus Kaier, et al.
Journal of Gastroenterology and Hepatology|June 5, 2024
LINAS-Score: prognostic model for mortality assessment in patients with cirrhotic liver and infected ascitesSilvia Würstle, Tillman Schneider, Siranush Karapetyan, et al.
Gut Microbes|February 17, 2022
Gut bacterial dysbiosis and instability is associated with the onset of complications and mortality in COVID-19David Schult, Sandra Reitmeier, Plamena Koyumdzhieva, et al.
Microbiology Spectrum|May 7, 2024
Erratum for Rothe et al., "Are enterococcal bloodstream infections an independent risk factor for a poorer 5-year survival or just a marker for severity of illness?-The Munich multicentric enterococci cohort"Kathrin Rothe, Tobias Bachfischer, Siranush Karapetyan, et al.
AIDS Care|April 26, 2021
Health-related quality-of-life in people living with HIV after switching to dual therapy with ritonavir-boosted darunavir + dolutegravir: a DUALIS sub-studyElisabeth Olliges, Bernhard Bührlen, Franz Fischer, et al.
Microbiology Spectrum|October 4, 2023
Are enterococcal bloodstream infections an independent risk factor for a poorer 5-year survival or just a marker for severity of illness?-The Munich multicentric enterococci cohortKathrin Rothe, Tobias Bachfischer, Siranush Karapetyan, et al.
Respiratory Research|April 24, 2021
SARS-CoV-2 serology increases diagnostic accuracy in CT-suspected, PCR-negative COVID-19 patients during pandemicJochen Schneider, Hrvoje Mijočević, Kurt Ulm, et al.
Open Forum Infectious Diseases|September 23, 2020
Efficacy and Safety of Switching to Dolutegravir With Boosted Darunavir in Virologically Suppressed Adults With HIV-1: A Randomized, Open-Label, Multicenter, Phase 3, Noninferiority Trial: The DUALIS StudyChristoph D Spinner, Tim Kümmerle, Jochen Schneider, et al.
Pageof 11

Showing results (81-90 of 107) with videos related to

Sort By:
Pageof 11
Cancer Research|December 22, 2011
Hedgehog signaling inhibition blocks growth of resistant tumors through effects on tumor microenvironmentEmanuela Heller, Michelle A Hurchla, Jingyu Xiang, et al.
HIV Research & Clinical Practice|March 2, 2022
Switching to a NRTI-free 2 drug regimen (2DR) -a sub-analysis of the 48 weeks DUALIS study on metabolic and renal changesMalte Monin, Tim Kümmerle, Jochen Schneider, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|September 21, 2021
Pre-medication with oral anticoagulants is associated with better outcomes in a large multinational COVID-19 cohort with cardiovascular comorbiditiesMarina Rieder, Nadine Gauchel, Klaus Kaier, et al.
Journal of Gastroenterology and Hepatology|June 5, 2024
LINAS-Score: prognostic model for mortality assessment in patients with cirrhotic liver and infected ascitesSilvia Würstle, Tillman Schneider, Siranush Karapetyan, et al.
Gut Microbes|February 17, 2022
Gut bacterial dysbiosis and instability is associated with the onset of complications and mortality in COVID-19David Schult, Sandra Reitmeier, Plamena Koyumdzhieva, et al.
Microbiology Spectrum|May 7, 2024
Erratum for Rothe et al., "Are enterococcal bloodstream infections an independent risk factor for a poorer 5-year survival or just a marker for severity of illness?-The Munich multicentric enterococci cohort"Kathrin Rothe, Tobias Bachfischer, Siranush Karapetyan, et al.
AIDS Care|April 26, 2021
Health-related quality-of-life in people living with HIV after switching to dual therapy with ritonavir-boosted darunavir + dolutegravir: a DUALIS sub-studyElisabeth Olliges, Bernhard Bührlen, Franz Fischer, et al.
Microbiology Spectrum|October 4, 2023
Are enterococcal bloodstream infections an independent risk factor for a poorer 5-year survival or just a marker for severity of illness?-The Munich multicentric enterococci cohortKathrin Rothe, Tobias Bachfischer, Siranush Karapetyan, et al.
Respiratory Research|April 24, 2021
SARS-CoV-2 serology increases diagnostic accuracy in CT-suspected, PCR-negative COVID-19 patients during pandemicJochen Schneider, Hrvoje Mijočević, Kurt Ulm, et al.
Open Forum Infectious Diseases|September 23, 2020
Efficacy and Safety of Switching to Dolutegravir With Boosted Darunavir in Virologically Suppressed Adults With HIV-1: A Randomized, Open-Label, Multicenter, Phase 3, Noninferiority Trial: The DUALIS StudyChristoph D Spinner, Tim Kümmerle, Jochen Schneider, et al.
Pageof 11